Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
Quick Facts
What This Study Found
Semaglutide added to automated insulin delivery in type 1 diabetes increased time in glucose target range by 4.8 percentage points without increasing hypoglycemia. Two cases of euglycemic ketosis occurred.
Key Numbers
28 randomized, 24 completed. Time in range (3.9-10.0 mmol/L) increased 4.8 percentage points (SD 7.6, P = 0.006). No increase in time below 3.9 (P = 0.19) or 3.0 mmol/L (P = 0.65). No DKA or severe hypoglycemia. 2 euglycemic ketosis episodes. Max dose 1 mg.
How They Did This
Randomized, double-blind, crossover trial. Semaglutide titrated up to 1 mg over 11 weeks, then 4 weeks on automated insulin delivery. Primary endpoint: time in target glucose range during last 4 weeks.
Why This Research Matters
Type 1 diabetes management remains challenging even with insulin pumps. This is the first blinded trial showing semaglutide can improve glucose control in T1D when paired with automated insulin delivery.
What This Study Doesn't Tell Us
Very small (28 randomized, 24 completed). Short treatment period (15 weeks total). Crossover design may have carryover effects. Euglycemic ketosis is a safety concern needing longer-term data.
Trust & Context
- Original Title:
- Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
- Published In:
- Nature medicine, 31(4), 1239-1245 (2025)
- Authors:
- Pasqua, Melissa-Rosina, Tsoukas, Michael A(3), Kobayati, Alessandra, Aboznadah, Wedyan, Jafar, Adnan, Haidar, Ahmad
- Database ID:
- RPEP-12971
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12971APA
Pasqua, Melissa-Rosina; Tsoukas, Michael A; Kobayati, Alessandra; Aboznadah, Wedyan; Jafar, Adnan; Haidar, Ahmad. (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.. Nature medicine, 31(4), 1239-1245. https://doi.org/10.1038/s41591-024-03463-z
MLA
Pasqua, Melissa-Rosina, et al. "Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.." Nature medicine, 2025. https://doi.org/10.1038/s41591-024-03463-z
RethinkPeptides
RethinkPeptides Research Database. "Subcutaneous weekly semaglutide with automated insulin deliv..." RPEP-12971. Retrieved from https://rethinkpeptides.com/research/pasqua-2025-subcutaneous-weekly-semaglutide-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.